One system, two routes
Glutathione is the cell's principal intracellular thiol antioxidant and a substrate for detoxification enzymes. There are two conceptually distinct ways to engage with that system from the outside: supply the building blocks the cell uses to synthesise it, or supply the molecule itself.
The precursor route works with cysteine and glycine, the two amino acids most often rate-relevant in glutathione synthesis. N-acetylcysteine (NAC) is a stable, well-characterised cysteine donor; glycine is the second substrate and is frequently under-considered.
Why the precursor route is mechanistically attractive
Glutathione synthesis is regulated intracellularly. Providing substrate lets the cell's own regulatory machinery determine how much is made, where, and under what conditions. That is a meaningful design property: it is support of an endogenous process rather than override of it.
Human work on combined glycine and NAC supplementation in older adults has reported changes in markers of glutathione status and oxidative stress. These are small, exploratory studies with defined populations, doses and durations — informative for mechanism, not sufficient for population-wide conclusions.
Why direct provision is a different question
Orally administered glutathione faces a pharmacokinetic problem: substantial hydrolysis and first-pass handling mean that the relationship between an oral dose and intracellular concentration is not straightforward. Some human studies report increases in body stores; others report no meaningful change. Formulation, dose, duration and the marker chosen all move the result.
This does not make direct provision meaningless. It makes it a distinct hypothesis with its own evidence base, which cannot be borrowed from precursor studies or vice versa.
Where the two strategies are wrongly merged
Marketing frequently collapses the distinction: precursor evidence is cited to justify a direct-provision product, or a direct antioxidant is described as though it regenerated the endogenous system. Biologically these are different interventions at different points in the same pathway.
A defensible position is to treat them as separate architectural layers with separate justifications — one addressing endogenous synthesis capacity, one addressing directly available redox support — and to state that the combination itself has not been studied as a finished formulation.
Limitations worth stating plainly
Study populations are frequently older adults or clinical cohorts, and results do not automatically transfer to healthy younger populations. Endpoints are usually biomarkers rather than outcomes. Durations are short. Sample sizes are small.
More antioxidant capacity is also not linearly better: redox signalling has physiological functions, and suppression of it is not an unambiguous benefit. Any honest reading of this literature ends in nuance rather than a recommendation.